Business Wire

ABB

5.6.2019 09:02:09 CEST | Business Wire | Press release

Share
ABB Azipod® Electric Propulsion Can Save $1.7 Million in Fuel Costs Annually, Study Shows

An independent study by marine consultancy Deltamarin revealed that the ABB Azipod® electric propulsion system for ferries could save up to $1.7 million in annual fuel costs per vessel, strengthening Azipod® propulsion’s market-leading position in sustainable marine technologies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190605005120/en/

By simulating a transit on seven existing ferry routes, researchers found that a ferry equipped with twin 10 MW mid-power range Azipod® units consumed less fuel compared to a similar vessel powered by a traditional shaftline propulsion system. Lower fuel consumption also means that the Azipod®-powered ferry would reduce CO2 emissions – by approximately 10,000 tons per year. This is equivalent to the amount of carbon dioxide emitted by about 2,200 passenger cars annually.

The global ferry industry, which transports 2.1 billion passengers every year, according to trade association Interferry, is facing increased pressure to meet the International Maritime Organization’s target of reducing annual emissions by 30 percent by 2025.

To help ferries improve energy efficiency and lower emissions, ABB is launching a new series of mid-power range Azipod® propulsion systems in June 2019. The latest Azipod® series will be available in the 7.5 to 14.5 MW power range and will fill the gap between the low and high-power range of Azipod® propulsors already in the market.

“We are continuously strengthening our portfolio of electric, digital and connected solutions that maximize the potential of ships and ultimately enable more sustainable operations,” said Peter Terwiesch, President of the Industrial Automation business at ABB, which offers solutions for a wide range of industries, including marine. “With the launch of the mid-power range Azipod® propulsion, we will be able to empower more shipowners to improve the performance of their vessels while lowering environmental impact.”

The Azipod® propulsion system, where the electric drive motor is in a submerged pod outside the ship hull, can rotate 360 degrees to increase maneuverability and operating efficiency, and has a proven ability to cut fuel consumption by up to 20 percent compared to traditional shaftline propulsion systems. Due to minimal noise and vibration, Azipod® propulsion also improves passenger and crew comfort. Azipod® propulsion systems have accumulated more than 15 million running hours, saving over 700,000 tons of fuel in the passenger cruise segment alone.

The latest Azipod® ‘M’ series is equipped with ABB’s fourth generation permanent magnet motors that draw on proven Azipod® propulsion technologies and have been refined to further increase power and maximize efficiency. The design simplicity of the system provides increased robustness and reliability, at the same time allowing for ease of maintenance.

With this expansion, the Azipod® propulsion family now covers the power range of 1-22 MW and is available for vessels from smaller crafts to icebreakers capable of independently operating in the harshest conditions. In addition to ferries and RoPax vessels that carry both vehicles and passengers, the mid-power range will also be applicable for larger offshore construction vessels, midsize cruise ships and shuttle tankers.

ABB – one of the world’s leading enablers of sustainable transportation – has already received several breakthrough orders in the ferry segment, including an Azipod® propulsion system for an LNG-powered Viking Line vessel due for delivery next year. Azipod® propulsion was also preferred by Finnish shipping company Wasaline for a recently ordered dual-fuel and battery power ferry, which will operate between Sweden and Finland.

“Building a future-proof, robust RoPax ferry requires proven technology that enables energy efficiency, saves valuable onboard space and provides increased passenger comfort. These features, coupled with superior maneuverability that would allow the ferry to operate a precise schedule crucial for a busy route, have made ABB’s Azipod® propulsion a natural choice for our newbuild project,” – said Peter Ståhlberg, CEO of Wasaline.

With over half of its global revenue generated from solutions that directly address the causes of climate change, ABB is at the forefront of sustainable development.

To watch the video, click here .

A summary of the Deltamarin study can be found here .

ABB (ABBN: SIX Swiss Ex) is a pioneering technology leader with a comprehensive offering for digital industries. With a history of innovation spanning more than 130 years, ABB is today a leader in digital industries with four customer-focused, globally leading businesses: Electrification, Industrial Automation, Motion, and Robotics & Discrete Automation, supported by its common ABB Ability™ digital platform. ABB’s market leading Power Grids business will be divested to Hitachi in 2020. ABB operates in more than 100 countries with about 147,000 employees. www.abb.com

Contact:

ABB Ltd Affolternstrasse 44 8050 Zurich Switzerland

Media Relations Phone: +41 43 317 71 11 Email: media.relations@ch.abb.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release

-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b

Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release

A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper

Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release

Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user

Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release

Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin

Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye